Long term investing in great businesses like Cytokinetics (NASDAQ:CYTK) can lead to significant share price growth, with a 381% gain in the last five years. Despite not being profitable, its 6.7% annual revenue growth has driven its stock performance.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing